Sunovion Pharma announces that it has entered into an exclusive agreement with Novartis for the US commercialization rights to three...
The FDA has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder, from Novartis, for the long-term maintenance treatment...
The FDA has approved Seebri Neohaler (glycopyrrolate) inhalation powder 15.6 µg, from Novartis, as monotherapy for the long-term maintenance treatment...
Novartis has launched its once-daily long-acting beta2 agonist Arcapta Neohaler (indacaterol inhalation powder) in the USA following its approval for...
New results from a pooled post-hoc sub-group analysis from three studies (INVOLVE, INHANCE and INLIGHT2) showed that Onbrez Breezhaler/Arcapta Neohaler...
Novartis has filed a new drug application (NDA) at the FDA for once a day Seebri Breezhaler (NVA 237) (glycopyrronium...
Novartis has announced the New England Journal of Medicine publication of the head-to-head FLAME study comparing the efficacy of once-daily...